Understanding Transthyretin Amyloid Cardiomyopathy | Bayer @BayerGlobal
Understanding Transthyretin Amyloid Cardiomyopathy | Bayer  @BayerGlobal
Uploaded February 2025 | Updated November 2026, 1 day ago
ATTR-CM is presented here as a rare, progressive heart disease that can be difficult to diagnose. The video explains transthyretin amyloid cardiomyopathy and the burden it can create for patients.

Bayer notes that ATTR-CM affects an estimated 400,000 people globally, while the true prevalence may be higher. The description also points to Bayer’s focus on care and quality of life for people living with the disease.
Understanding Transthyretin Amyloid Cardiomyopathy | BayerClosing Europe’s Innovation Gap in Health and AgricultureHair loss is about more than what you see on the surface - it is deeply personal & often emotionalSkills Training and Career Opportunities for Rural Youth | Bayer IndiaMissing From the Room: How Bayer Is Advancing Cancer ResearchVirtual Tour: Bayer Innovation Experience at the Crop Science R&D Center in Chesterfield, MissouriBayer’s Nutrient Gap Initiative: Expanding Access to Vitamins & Minerals by 2030Science Is Boss: CoverCress — From Weed to Renewable Biofuel Crop | Bill Anderson x Jim HedgesLiving With Wet Age-Related Macular Degeneration | BayerHow to Get All the Nutrients You and Your Baby NeedBayer CEO Bill Anderson shares Half Year 2026 Results | 90 Days in 90 SecondsFood Security in Africa: Helping Smallholder Farmers Produce More With Less | Bayer Crop Science
Bayer Global |

Understanding Transthyretin Amyloid Cardiomyopathy | Bayer

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER